219例药物性肝损伤患者临床特征和预后分析*

doi:10.3969/j.issn.1672-5069.2024.02.013

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (2): 210-213.doi: 10.3969/j.issn.1672-5069.2024.02.013

219例药物性肝损伤患者临床特征和预后分析^*

梁丹丹, 江建宁, 黄锦妮, 龙诗雨, 董国珍, 苏曼, 李继娇, 滕春玲, 张萍, 苏明华

530021 南宁市广西医科大学第一附属医院感染性疾病科

收稿日期:2022-03-11 出版日期:2024-02-10 发布日期:2024-03-08
通讯作者: 苏明华,E-mail:smh9292@163.com
作者简介:梁丹丹,女,28岁,医学硕士。主要从事药物性肝损害防治研究
基金资助:
^*广西壮族自治区医疗卫生适宜技术开发与推广应用项目(编号:S2019108);广西壮族自治区教育厅高等学校科研项目(编号:YB2014064);南宁市青秀区科学研究与技术开发计划项目(编号:2013ZH02)

Clinical feature and prognosis of patients with drug-induced liver injury: An analysis of 219 cases

Liang Dandan, Jiang Jianning, Huang Jinni, et al.

Department of Infectious Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

Received:2022-03-11 Online:2024-02-10 Published:2024-03-08

摘要/Abstract

摘要： 目的分析药物性肝损伤(DILI)患者的临床特征, 为临床合理用药、早期发现及诊断提供参考。方法 2012年1月～2020年12月广西医科大学第一附属医院住院治疗的诊断为DILI患者219例, 经Roussel Uclaf因果关系评估方法(RUCAM)评分≥6分诊断, 并将肝损伤程度分为1级(轻度)、2级(中度)和3级、4级、5级(重度)。结果在本组219例DILI患者中, 最常见的可疑致病药物为中药类(30.1%)、抗结核药物(12.3%)、抗生素(11.9%)、抗肿瘤及免疫抑制剂(7.8%)和解热镇痛药(6.4%);肝细胞损伤型160例, 胆汁淤积型42例, 混合型17例;三型性别和年龄分布差异无统计学意义(P＞0.05);严重程度1级100例, 2级32例, 3级以上87例;胆汁淤积型和混合型患者重度肝损伤占比分别为57.1%和53.0%, 均显著高于肝细胞损伤型的33.7%(P＜0.05);肝细胞损伤型治愈或好转率为93.8%, 显著高于胆汁淤积型的61.9%或混合型的70.6%(P＜0.01)。结论了解临床常导致DILI的可疑药物、临床类型和病情评估方法对于预防、早期诊断和及时处理都很重要, 需要进一步规范处置流程, 防止病情进展。

关键词: 药物性肝损伤, 临床特征, 临床分型, 预后

Abstract: Objective The purpose of this study was to summarize the clinical features and prognosis of patients with drug-induced liver injury(DILI). Methods The clinical data of 219 hospitalized patients with DILI was analyzed, who were encountered in First Affiliated Hospital, Guangxi Medical University between January 2012 and December 2020. The diagnosis was made by the RUCAM score ≥6. The suspect medicines, clinical features, disease severity and outcomes were retrospectively analyzed, and the disease severity was classified as mild, moderate and severe. Results In our series of 219 patients with DILI, the top five suspected medicines that most frequently caused DILI were Chinese herbal medicine (30.1%), anti-tuberculosis agents (12.3%), antibiotics (11.9%), anti-tumor and immunosuppressive medicines (7.8%) and antipyretic analgesics (6.4%); the clinical types included hepatocyte injury type in 160 cases, cholestasis type in 42 cases and mixed type in 17 cases; there was no significant differences in gender and age distribution among the three types of clinical types (P>0.05); there were 100 patients with disease severity of grade 1, 32 patients with grade 2 and 87 patients with grade 3 or above; the percentages of severe type in patients with cholestasis type and mixed type were 57.1% and 53.0%, both significantly higher than 33.7%(P＜0.05) in patients with hepatocyte injury; the recovery rate in patients with hepatocyte injury was 93.8%, much higher than 61.9% in patients with cholestasis type or 70.6% in patients with mixed type (P＜0.01). Conclusion The common suspected medicines which could lead to DILI in clinical practice are mainly traditional Chinese herbal medicines, anti-tuberculosis agents and antibiotics. The clinical classification is mainly hepatocellular injury type, and the proportions of severe liver injury in patients with cholestasis and mixed type are significantly higher than that in those with hepatocyte injury type. The outcomes of patients with hepatocyte injury is relatively promising.

Key words: Drug-induced liver injury, Clinical features, Clinical types, Prognosis

梁丹丹, 江建宁, 黄锦妮, 龙诗雨, 董国珍, 苏曼, 李继娇, 滕春玲, 张萍, 苏明华. 219例药物性肝损伤患者临床特征和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 210-213.

Liang Dandan, Jiang Jianning, Huang Jinni, et al.. Clinical feature and prognosis of patients with drug-induced liver injury: An analysis of 219 cases[J]. Journal of Practical Hepatology, 2024, 27(2): 210-213.

参考文献

[1] Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol, 2007, 102(11):2459-2463.
[2] Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology,2013,144(7):1419-1425, 1425.e1411-1413; quiz e1419-1420.
[3] Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology,2002,36(2):451-455.
[4] Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol,2012,107(9):1380-1387.
[5] De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther, 2006, 24(8):1187-1195.
[6] de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol, 2004, 58(1):71-80.
[7] Shen T, Liu Y, Shang J, et al. Incidence andetiology of drug-induced liver injury in mainland China. Gastroenterology, 2019, 156(8):2230-2241.e2211.
[8] 于乐成,茅益民,陈成伟.药物性肝损伤诊治指南.中华肝脏病杂志,2015,23(11):810-820.
[9] Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology, 2009, 49(6):2001-2009.
[10] Zhou Y, Yang L, Liao Z, et al. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol,2013,25(7):825-829.
[11] 刘丽娜,赵建学,陆玮婷,等.138例药物性肝损伤患者影响预后的因素分析.实用肝脏病杂志,2015,18(2):160-163.
[12] 何文昌,张克恭,赵凡惠,等.290例药物性肝损伤患者临床特征分析.实用肝脏病杂志,2020,23(4):540-543.
[13] Floreani A,Bizzaro D,Shalaby S et al. Sex disparity and drug-induced liver injury.Dig Liver Dis, 2023, 55: 21-28.
[14] EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol, 2019, 70(6):1222-1261.
[15] Low EXS, Zheng Q, Chan E, et al. Drug induced liver injury: East versus west - a systematic review and meta-analysis. Clin Mol Hepatol, 2020, 26(2):142-154.
[16] Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol, 2010, 105(11):2396-2404.
[17] Chirapongsathorn S,Sukeepaisarnjaroen W,Treeprasertsuk S, et al. Characteristics ofdrug-induced liver injury in chronic liver disease: Results from the Thai Association for the Study of the Liver (THASL) DILI Registry. J Clin Transl Hepatol, 2023, 11: 88-96.
[18] Abdulkhaleq FM, Alhussainy TM, Badr MM, et al. Antioxidative stress effects of vitamins C, E, and B₁₂, and their combination can protect the liver against acetaminophen-induced hepatotoxicity in rats. Drug Des Devel Ther, 2018,12:3525-3533.
[19] Shahnazarian V, Ramai D, Reddy M. A rare case of ibuprofen-induced acute liver injury. Cureus, 2018,10(8):e3225.
[20] Yin Y, Zhang Y, Li H, et al. Triterpenoids from fruits of Sorbus pohuashanensis inhibit acetaminophen-induced acute liver injury in mice. Biomed Pharmacother, 2018,109:493-502.
[21] Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology, 2015, 148(7):1340-1352,e1347.
[22] Xu P, Zhou H, Li YZ, et al. Baicalein enhances the oral bioavailability and hepatoprotective effects of silybin through the inhibition of efflux transporters BCRP and MRP2. Front Pharmacol, 2018,9:1115.

219例药物性肝损伤患者临床特征和预后分析^*

Clinical feature and prognosis of patients with drug-induced liver injury: An analysis of 219 cases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	卜玲玲, 殷燕, 潘丹烨, 陈晨. 自身免疫性肝炎与原发性胆汁性肝硬化合并干燥综合征患者临床特征比较^*[J]. 实用肝脏病杂志, 2024, 27(2): 206-209.
[2]	张天祺, 王敏, 杨娜, 朱怀军. 应用替加环素治疗重症感染患者DILI发生及其影响因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 214-217.
[3]	刘松涛, 孟庆华, 刘梅, 韩亚男, 王金环, 闾军. 急性/亚急性肝衰竭患者急性肾损伤发生率和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 222-225.
[4]	任浩, 刘力伟, 施维, 刘波, 吴于青, 吕芹. 苦黄注射液预防抗结核药物导致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 56-59.
[5]	王琦, 周峰, 袁宇初, 薛美珠. 肝豆状核变性患者临床特征及基因突变位点分析^*[J]. 实用肝脏病杂志, 2024, 27(1): 60-63.
[6]	何圣科, 蒲江汉, 冯海玲, 吴大平, 陈绵军, 陈辉. 肝细胞癌组织HOXC9和KIF4A表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(1): 84-87.
[7]	张玥, 宁玲, 李文渊, 郑晓玮, 刘洪涛, 张振华, 李磊. 血清HBsAg阳性者接受肾移植术120周预后随访报告^*[J]. 实用肝脏病杂志, 2023, 26(6): 797-800.
[8]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[9]	李菲, 陈辛未, 李琦. HBV相关慢加急性肝衰竭患者血清GP73、suPAR和AT-Ⅲ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 847-850.
[10]	杨婉, 丁莉, 罗珂, 刘美. 肝细胞癌患者癌组织CK7和Glypican-3表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 883-886.
[11]	孙岩, 张鑫, 李国宾, 闫尚伦, 徐良. 接受根治性肝切除术治疗的肝内胆管细胞癌患者肿瘤组织成纤维细胞生长因子受体2表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 907-910.
[12]	李玲, 何小琪, 高勇, 方春田, 盛天驰, 王燕, 郑红梅. 孕期药物性肝损伤患者血清miR-21、Nrf2和HO-1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 662-665.
[13]	莫俊俏, 林景, 羊莉. 水飞蓟宾胶囊联合多烯磷脂酰胆碱治疗抗结核药物所致药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 666-669.
[14]	裴素娟, 郭锦辉, 魏晓霞. 综合医院住院患者药物性肝损伤发生致病药物及影响肝损伤严重程度的因素分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 670-673.
[15]	常凯, 黄亚秋, 于立丽, 熊建新, 杨明. 肝硬化并发肝肾综合征患者血清细胞因子和外周血淋巴细胞亚群变化及短期预后分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 678-681.